The Endocrine Society's recent Scientific Statement on postmenopausal hormone therapy highlights the dangers of calculating risks and benefits associated with hormone therapy for women in early menopause on the basis of evidence from previous studies. But does it provide a quantum shift in the clinician's perception of risk versus benefit from hormone therapy?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rossouw, J. E. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321–333 (2002).
Santen, R. J. et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J. Clin. Endocrinol. Metab. 95 (Suppl. 1), S1–S66 (2010).
Pilon, D., Castilloux, A. M. & LeLorier, J. Estrogen replacement therapy: determinants of persistence with treatment. Obstet. Gynecol. 97, 97–100 (2001).
Santen, R. J. & Allred, D. C. The estrogen paradox. Nat. Clin. Pract. Endocrinol. Metab. 3, 496–497 (2007).
Barrett-Connor, E. et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med. 355, 125–137 (2006).
Ellis, M. J. et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA 302, 774–780 (2009).
Simon, J. A. Postmenopausal estrogen therapy: which route to take? Nat. Clin. Pract. Endocrinol. Metab. 5, 146–147 (2009).
Simon, J. A., Nahum, G. G., Stanislaw, H. & Gaines, T. The breast cancer “plunge” after initial publication of the WHI results: an alternative explanation. Maturitas 66, 277–284 (2010).
Hodis, H. N. Assessing benefits and risks of hormone therapy in new evidence, especially with regard to the heart. Cleve. Clin. J. Med. 75 (Suppl. 4), S3–S12 (2008).
Galloway, V. A. & Brodsky, S. L. Caring less, doing more: the role of therapeutic detachment with volatile and unmotivated clients. Am. J. Psychother. 57, 32–38 (2003).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Simon, J. Postmenopausal hormone therapy: risks versus benefits reassessed. Nat Rev Endocrinol 6, 661–663 (2010). https://doi.org/10.1038/nrendo.2010.191
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2010.191
